Kilitch Drugs (India) Limited (NSE:KILITCH)

Market Cap	6.89B +12.6%
Revenue (ttm)	2.34B +11.9%
Net Income	240.91M -13.8%
EPS	6.88 -20.1%
Shares Out	n/a
PE Ratio	28.71
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,938
Open	200.55
Previous Close	200.54
Day's Range	195.21 - 202.00
52-Week Range	117.25 - 267.90
Beta	0.34
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Kilitch Drugs (India)

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 236
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: KILITCH

Financial Performance

In fiscal year 2026, Kilitch Drugs (India)'s revenue was 2.35 billion, an increase of 18.74% compared to the previous year's 1.98 billion. Earnings were 301.66 million, an increase of 12.98%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error